Cargando…
Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types
Innate drug sensitivity in healthy cells aids identification of lineage specific anti-cancer therapies and reveals off-target effects. To characterize the diversity in drug responses in the major hematopoietic cell types, we simultaneously assessed their sensitivity to 71 small molecules utilizing a...
Autores principales: | Majumder, Muntasir M., Leppä, Aino-Maija, Hellesøy, Monica, Dowling, Paul, Malyutina, Alina, Kopperud, Reidun, Bazou, Despina, Andersson, Emma, Parsons, Alun, Tang, Jing, Kallioniemi, Olli, Mustjoki, Satu, O’Gorman, Peter, Wennerberg, Krister, Porkka, Kimmo, Gjertsen, Bjørn T., Heckman, Caroline A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271564/ https://www.ncbi.nlm.nih.gov/pubmed/31439679 http://dx.doi.org/10.3324/haematol.2019.217414 |
Ejemplares similares
-
Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2020) -
Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients
por: Tierney, Ciara, et al.
Publicado: (2021) -
Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
por: Malani, Disha, et al.
Publicado: (2022) -
Using Proteomics Data to Identify Personalized Treatments in Multiple Myeloma: A Machine Learning Approach
por: Katsenou, Angeliki, et al.
Publicado: (2023) -
Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers
por: Dunphy, Katie, et al.
Publicado: (2021)